Lakefront Biotherapeutics NV (MEX:GLPGN) Cyclically Adjusted Revenue per Share: MXN188.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GLPGN Lakefront Biotherapeutics NV MEX:GLPGN
58 GF Score
Price MXN665.65
GF Value MXN3,143.44
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Cyclically Adjusted Revenue per Share?

Lakefront Biotherapeutics NV MEX:GLPGN 58 Cyclically Adjusted Revenue per Share is MXN188.66 as of Mar. 2026. GuruFocus rates MEX:GLPGN with a GF Score™ of 58/100 and a GF Value™ of MXN3,143.44. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lakefront Biotherapeutics NV's adjusted revenue per share for the three months ended in Mar. 2026 was MXN2.051. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN188.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lakefront Biotherapeutics NV's average Cyclically Adjusted Revenue Growth Rate was 27.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lakefront Biotherapeutics NV was 9.00% per year. The lowest was 1.20% per year. And the median was 1.90% per year.

As of today (2026-08-09), Lakefront Biotherapeutics NV's current stock price is MXN665.65. Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN188.66. Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio of today is 3.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lakefront Biotherapeutics NV was 35.11. The lowest was 3.15. And the median was 6.44.


Lakefront Biotherapeutics NV  (MEX:GLPGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=665.65/188.66
=3.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lakefront Biotherapeutics NV was 35.11. The lowest was 3.15. And the median was 6.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lakefront Biotherapeutics NV Cyclically Adjusted Revenue per Share Related Terms


Lakefront Biotherapeutics NV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Cyclically Adjusted Revenue per Share Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 109.39 97.11 143.32 174.97

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.13 164.17 136.05 174.97 188.66

MEX:GLPGN vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio falls into.


MEX:GLPGN
58GF Score
Lakefront Biotherapeutics NV MEX:GLPGN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lakefront Biotherapeutics NV's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.051/136.5600*136.5600
=2.051

Current CPI (Mar. 2026) = 136.5600.

Lakefront Biotherapeutics NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 12.408 102.267 16.569
201609 5.107 102.118 6.829
201612 37.425 102.614 49.806
201703 14.799 103.972 19.438
201706 10.897 103.902 14.322
201709 11.622 104.170 15.236
201712 17.965 104.804 23.408
201803 16.627 105.419 21.539
201806 21.997 106.063 28.322
201809 39.067 106.618 50.038
201812 39.641 107.252 50.473
201903 13.249 107.876 16.772
201906 23.205 107.896 29.370
201909 230.080 107.470 292.358
201912 34.131 108.065 43.131
202003 36.062 108.550 45.367
202006 39.828 108.540 50.110
202009 50.639 108.441 63.770
202012 57.804 108.511 72.746
202103 41.450 109.522 51.683
202106 51.160 110.305 63.337
202109 23.697 111.543 29.012
202112 -29.581 114.705 -35.217
202203 44.927 118.620 51.722
202206 44.523 120.948 50.270
202209 41.202 124.120 45.332
202212 -57.569 126.578 -62.109
202303 17.048 126.528 18.400
202306 17.066 125.973 18.500
202309 17.122 127.083 18.399
202312 16.947 128.292 18.039
202403 17.102 130.552 17.889
202406 23.430 130.691 24.482
202409 19.716 130.968 20.558
202412 25.036 132.346 25.833
202503 25.187 134.348 25.602
202506 21.469 133.495 21.962
202509 23.285 133.740 23.776
202512 288.190 135.070 291.369
202603 2.051 136.560 2.051

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN188.66 mean?
Lakefront Biotherapeutics NV (MEX:GLPGN) has a Cyclically Adjusted Revenue per Share of MXN188.66 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share too high?
Lakefront Biotherapeutics NV's current Cyclically Adjusted Revenue per Share is MXN188.66. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share of MXN188.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Cyclically Adjusted Revenue per Share is MXN188.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Lakefront Biotherapeutics NV (MEX:GLPGN) has a current Cyclically Adjusted Revenue per Share of MXN188.66. The stock's GF Value™ is MXN3,143.44, compared to a current price of MXN665.65 — trading 78.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN188.66. Lakefront Biotherapeutics NV's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (MEX:GLPGN), the current Cyclically Adjusted Revenue per Share is MXN188.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (MEX:GLPGN) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of MXN665.65 is trading 78.8% below its estimated GF Value™ of MXN3,143.44.

Key valuation signals for MEX:GLPGN:

  • Cyclically Adjusted Revenue per Share: MXN188.66
  • GF Value™: MXN3,143.44 vs. price of MXN665.65 (78.8% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the MEX:GLPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
58GF Score

Get the complete analysis for MEX:GLPGN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN665.65
Price
MXN3,143.44
GF Value